found that the occurrence of hypertension [grade‡ 3 according to the National Cancer
Institute—Common Toxicity Criteria (NCI-CTC)[13]] was associated with a higher response …

Arterial hypertension is a commonly reported side-effect in all clinical trials testing all
inhibitors of angiogenesis and especially inhibitors of vascular endothelial growth factor …

Background. Hypertension is a common toxicity of bevacizumab, but the frequency of
assessment of blood pressure and standardized grading remain to be defined. This study …

Any of a number of therapeutic agents or chemical substances can induce transient or more
long-lasting forms of hypertension. Drugs that cause hypertension do so by either …

3039 Background: HTN is associated with anti-VEGF treatment (Tx), but this association has
not been well studied. To assess the prognostic and predictive importance of BV-related …

Background: Several phase-III studies have shown improvements in terms of progression-
free survival (PFS) with bevacizumab when added to chemotherapy in advanced breast …

3020 Background: Bevacizumab is a monoclonal Ab to the vascular endothelial growth
factor (VEGF). VEGF increases vessel permeability by stimulating endothelial nitric oxide …

Few predictive factors for efficacy of vascular endothelial growth factor pathway-targeted
therapies have been identified. We studied whether bevacizumab treatment-related …

Background: Antiangiogenic therapy is routinely used in a variety of cancer entities.
Hypertension is the most common side effect of all currently available antiangiogenic …

Background. Hypertension is associated with antivascular endothelial growth factor
treatment, but the clinical implications of hypertension are uncertain. To assess the …